Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma.

Kenji InoueMinako ShiokawaShiho Kunimatsu-SanukiJungshin KangTakehiko UrakiGoji TomitaKyoko Ishida

Published in: Japanese journal of ophthalmology (2024)

After the administration of omidenepag isopropyl, IOP in patients with NTG decreased within 3 years, visual fields were maintained, and safety was satisfactory. Thus, omidenepag isopropyl can be used as the first-line treatment for patients with NTG.

Keyphrases